<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS202033</article-id><article-id pub-id-type="doi">10.1101/2024.12.10.627805</article-id><article-id pub-id-type="archive">PPR954416</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Enhancer IncRNA LOC730338 limits the innate immune response against lymphoma cells, inhibiting ADAR2-dependent alternative transcription</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cascione</surname><given-names>Luciano</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Guidetti</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ramnarayanan</surname><given-names>Sunandini</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Rinaldi</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Spriano</surname><given-names>Filippo</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zadro</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Tarantelli</surname><given-names>Chiara</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Munz</surname><given-names>Nicolas</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Arribas</surname><given-names>Alberto J.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Rory</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bertoni</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A7">7</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Napoli</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01dpyn972</institution-id><institution>Institute of Oncology Research</institution></institution-wrap>, Faculty of Biomedical Sciences, USI, <city>Bellinzona</city>, <country country="CH">Switzerland</country></aff><aff id="A2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002n09z45</institution-id><institution>SIB Swiss Institute of Bioinformatics</institution></institution-wrap>, <city>Lausanne</city>, <country country="CH">Switzerland</country></aff><aff id="A3"><label>3</label>School of Biology and Environmental Science, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05m7pjf47</institution-id><institution>University College Dublin</institution></institution-wrap>, <city>Dublin</city>, <postal-code>D04 V1W8</postal-code>, <country country="IE">Ireland</country></aff><aff id="A4"><label>4</label>Conway Institute for Biomolecular and Biomedical Research, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05m7pjf47</institution-id><institution>University College Dublin</institution></institution-wrap>, <country country="IE">Ireland</country></aff><aff id="A5"><label>5</label>The SFI Centre for Research Training in Genomics Data Science, Dublin, Ireland</aff><aff id="A6"><label>6</label>Laboratories for Translational Research, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00sh19a92</institution-id><institution>Ente Ospedaliero Cantonale</institution></institution-wrap>, <city>Bellinzona</city>, <country country="CH">Switzerland</country></aff><aff id="A7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tty5b50</institution-id><institution>Oncology Institute of Southern Switzerland</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00sh19a92</institution-id><institution>Ente Ospedaliero Cantonale</institution></institution-wrap>, <city>Bellinzona</city>, <country country="CH">Switzerland</country></aff><author-notes><corresp id="CR1"><label>*</label> <bold>Co-corresponding authors:</bold> -Dr Sara Napoli, Institute of Oncology Research, via Francesco Chiesa 5, 6500 Bellinzona, Switzerland. <email>sara.napoli@ior.usi.ch</email>, -Prof. Francesco Bertoni, Institute of Oncology Research, via Francesco Chiesa 5, 6500 Bellinzona, Switzerland <email>francesco.bertoni@ior.usi.ch</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>18</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>12</day><month>12</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Chronic antigenic stimulation is central to marginal zone lymphoma (MZL) development. While the pharmacological inhibition of the B-cell receptor (BCR) signaling is initially effective, secondary resistance frequently develops. We conducted a CRISPR interference (CRISPRi) screen investigating enhancer-associated long non-coding RNAs (elncRNAs) in MZL cells to identify transcripts crucial to shape their dependence on BCR pathway activation. We identified LOC730338, an elncRNA associated with A-to-I RNA editing, which we renamed ADARreg. Silencing ADARreg re-sensitized tumor cells to BCR pathway inhibition by modulating ADAR2 nuclear translocation and altering intronic RNA editing. The process preferentially affected genes that enhance immune responses, such as STING, IRF3, and p65. ADARreg knockdown also increased lymphoma cell sensitivity to NK cell-mediated cytotoxicity. Our results indicate that targeting elncRNAs like ADARreg represents a potential strategy to overcome drug resistance in lymphoma, also opening new therapeutic opportunities for immunotherapy.</p></abstract></article-meta></front><body><p id="P2">Marginal zone Lymphoma (MZL) derives from MZ B cells under chronic inflammation and prolonged B cell receptor (BCR) activation from persistent infections or autoimmune diseases [<xref ref-type="bibr" rid="R1">1</xref>]. A hallmark of MZL is the interaction of tumor cells with the microenvironment, a complex network of various cell types, including T cells, which communicate through soluble factors like cytokines and chemokines. BCR signaling plays a key role in shaping these interactions and activating downstream pathways like NF-kB [<xref ref-type="bibr" rid="R2">2</xref>], to sustain lymphoma growth [<xref ref-type="bibr" rid="R3">3</xref>]. Indeed, the pharmacological inhibition of BCR signaling, particularly through Bruton’s tyrosine kinase (BTK) inhibition with the first-in-class ibrutinib and newer agents, is an effective therapeutic option for MZL patients as well as for other lymphoid neoplasms [<xref ref-type="bibr" rid="R4">4</xref>–<xref ref-type="bibr" rid="R6">6</xref>]. However, resistance frequently develops [<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R8">8</xref>], and, in lymphoma cells, it is frequently sustained by, in lymphoma cells, it is frequently sustained by epigenetic reprogramming [<xref ref-type="bibr" rid="R9">9</xref>–<xref ref-type="bibr" rid="R12">12</xref>].</p><p id="P3">Non-coding RNAs (ncRNAs), particularly enhancer-associated long non-coding RNAs (elncRNAs), play key roles in regulating gene expression [<xref ref-type="bibr" rid="R13">13</xref>]. The elncRNAs are transcribed from enhancer regions and act as transcription regulators in a tissue-specific and developmentally regulated manner [<xref ref-type="bibr" rid="R14">14</xref>]. They derive from super-enhancers (SEs), large clusters of highly acetylated enhancers bound by transcription factors, regulating key differentiation genes [<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R16">16</xref>]. ElncRNAs often stabilize protein complexes <italic>in cis</italic> but can also acquire <italic>in trans</italic> activity, affecting both nuclear and cytoplasmatic additional functions [<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R18">18</xref>].</p><p id="P4">Here, we aimed to identify elncRNAs modulating the transcriptional reprogramming in ibrutinib-resistant splenic MZL (SMZL) via a screen based on the Clustered Regularly Interspaced Short Palindromic Repeats Interference (CRISPRi) technology. Among the identified transcripts, the lncRNA LOC730338 (AC011294.3/ENSG00000233539) emerged due to its previously identified role in regulating A-to-I RNA editing in B cells [<xref ref-type="bibr" rid="R19">19</xref>]. We show that it likely acts as a negative regulator of ADARB1 and, to a lesser extent, ADAR, genes that encode the adenosine deaminases ADAR2 and ADAR1, respectively [<xref ref-type="bibr" rid="R19">19</xref>]. Based on this, we renamed it ADARreg and demonstrated its role in modulating the sensitivity to ibrutinib and also for an immune-suppressive capacity.</p><sec id="S1" sec-type="results"><title>Results</title><sec id="S2"><title>Acquired ibrutinib-resistance in SMZL cells is associated with changes in super-enhancer activation</title><p id="P5">The VL51 cell line, which originated from a patient with a SMZL [<xref ref-type="bibr" rid="R20">20</xref>], was cultured for up to nine months under increasing doses of ibrutinib, leading to secondary resistance to BTK inhibitors and other BCR pathway-targeting drugs, such as the PI3K inhibitors idelalisib, duvelisib and copanlisib [<xref ref-type="bibr" rid="R21">21</xref>]. <italic>In vitro</italic> BCR stimulation revealed that, in ibrutinib-resistant cells, NF-κB signaling showed reduced BCR dependency compared to parental cells (<xref ref-type="supplementary-material" rid="SD1">Fig.S1A</xref>).</p><p id="P6">To study the epigenetic remodeling of BCR-blocked cells, we investigated the enhancer activity in ibrutinib-resistant VL51, using ChIP-sequencing to profile histone modifications (H3K27ac, H3K4me1, and H3K4me3). We identified 33,264 H3K27ac peaks: 20,950 common, 2,830 unique to parental cells, and 541 to resistant cells (<xref ref-type="fig" rid="F1">Fig.1A</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Bona fide enhancers were defined by the presence of H3K4me1 and the absence of H3K4me3. Comparing ibrutinib-resistant cells to their parental counterparts, we found that resistant cells lost 1,329 enhancers and gained 144 new ones (<xref ref-type="fig" rid="F1">Fig.1A, B</xref>). Taking advantage of the RNAseq from parental and derivative cells, we examined the genes within 40 kb of these differentially activated enhancers. Loss of enhancers was linked to the downregulation of key genes, including CDKN2A, CDKN2B, and MAP3K14, with the most notable decrease observed in NLRP4, a pattern-recognition receptor (PRR) involved in immune activation (<xref ref-type="fig" rid="F1">Fig.1C</xref>, left) [<xref ref-type="bibr" rid="R22">22</xref>]. A few genes near newly activated enhancers were significantly upregulated in resistant cells (<xref ref-type="fig" rid="F1">Fig.1C</xref>, right). This suggested that additional non-coding transcripts might be associated with these enhancer gains.</p></sec><sec id="S3"><title>Identification of elncRNAs associated with ibrutinib resistance</title><p id="P7">SEs, densely bound by transcription factors and highly acetylated, regulate crucial genes and are the main source of elncRNAs. Using the ROSE algorithm [<xref ref-type="bibr" rid="R23">23</xref>], we identified 1,345 SEs from H3K27Ac ChIP-Seq data. (<xref ref-type="supplementary-material" rid="SD1">Fig.S1B</xref>). To determine how many SEs were associated with elncRNA production, we reconstructed the transcriptomes of parental and ibrutinib-resistant VL51 cells using total RNA-Seq profiling. We included a VL51 derivative resistant to PI3Kδ inhibitors [<xref ref-type="bibr" rid="R11">11</xref>] to expand our analysis beyond ibrutinib-resistance. By analyzing ribosomal RNA-depleted libraries, we detected polyadenylated and non-polyadenylated transcripts and identified novel and known transcripts associated with SEs (<xref ref-type="supplementary-material" rid="SD1">Fig.S1B</xref>). We defined elncRNAs as any transcript detectable within an active SE in either parental or resistant cells. We assigned a transcription start site (TSS) based on the FANTOM project CAGE dataset [<xref ref-type="bibr" rid="R24">24</xref>] (<xref ref-type="supplementary-material" rid="SD1">Fig S1B</xref>). We excluded transcripts annotated as protein-coding genes but included antisense or sense intronic transcripts. We identified 427 elncRNAs, including 74 novel transcripts not listed in GENCODE (<xref ref-type="supplementary-material" rid="SD1">Fig.S1B</xref>). Of these, 13% (45 elncRNAs) were lost, and 9% (30 elncRNAs) were gained in the ibrutinib-resistant cells (<xref ref-type="supplementary-material" rid="SD1">Fig.S1A</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S2</xref>).</p></sec><sec id="S4"><title>Functional screening of elncRNAs linked to BCR blockade</title><p id="P8">To identify elncRNAs associated with BCR blockade, we performed a genome-wide CRISPRi screen in both parental and ibrutinib-resistant cells (<xref ref-type="fig" rid="F2">Fig.2A</xref>). We designed a custom library of paired guide RNAs (pgRNAs) that targeted 255 annotated elncRNAs and 57 novel ones (<xref ref-type="fig" rid="F2">Fig.2B</xref>). The library also included pgRNAs targeting 225 lincRNAs differentially expressed between parental and resistant cells, 68 essential genes as positive controls, and 33 non-expressed transcripts as negative controls. The whole library investigated 659 transcripts (<xref ref-type="fig" rid="F2">Fig.2B</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S2</xref>). The pgRNAs were designed to target regions within -300 to +300 base pairs around the TSSs by a defective Cas9 fused with the repressor ZIM3 (dCas9-KRAB-ZIM3) [<xref ref-type="bibr" rid="R25">25</xref>] (<xref ref-type="fig" rid="F2">Fig.2A</xref>, <xref ref-type="supplementary-material" rid="SD1">S1C</xref>), allowing transcriptional repression without inducing DNA damage [<xref ref-type="bibr" rid="R25">25</xref>].</p><p id="P9">After elncRNA CRISPRi library infection (<xref ref-type="supplementary-material" rid="SD1">Fig.S1D</xref>), parental and resistant cells were treated with either ibrutinib or DMSO for two weeks (<xref ref-type="fig" rid="F2">Fig.2C</xref>). We analyzed two replicates per condition at three time points (6, 10, and 14 days) compared to time 0 (<xref ref-type="fig" rid="F2">Fig.2C</xref>). The effects of specific transcripts on cell survival and BCR dependency, assessed by ibrutinib sensitivity, were measured through pgRNAs enrichment overtime, represented by β score (<xref ref-type="fig" rid="F2">Fig.2D</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S3</xref>). Positive β values indicated that transcripts impaired proliferation or increased drug sensitivity, negative β values the opposite. The high β correlation for positive controls across replicates validated the robustness of our approach (<xref ref-type="supplementary-material" rid="SD1">Fig.S1E</xref>).</p><p id="P10">The β correlation for elncRNA targets was consistent, albeit higher in parental cells, possibly reflecting greater heterogeneity in the resistant population (<xref ref-type="supplementary-material" rid="SD1">Fig.S1F</xref>). Multi-dimensional scaling (MDS) plots showed lincRNA silencing differentiated parental from resistant cells, especially after 14 days (<xref ref-type="supplementary-material" rid="SD1">Fig.S1G</xref>). Similarly, elncRNA silencing discriminated resistant from parental cells starting as early as day 6 (<xref ref-type="fig" rid="F2">Fig.2D</xref>). Notably, some elncRNAs affected resistant cell survival only with drug exposure (<xref ref-type="fig" rid="F2">Fig.2D</xref>).</p><p id="P11">The distribution of β scores in parental and resistant cells exposed to ibrutinib showed concordance of many transcripts modulating the drug response, especially among lincRNAs (<xref ref-type="fig" rid="F2">Fig 2E</xref>, left). However, some elncRNAs peculiarly affected ibrutinib efficacy in resistant or parental cells. Noteworthy, silencing AC011294.3 (ADARreg) (<xref ref-type="supplementary-material" rid="SD1">FigS2A</xref>) and RP11-96H19.1 (lncPCED1b) (<xref ref-type="supplementary-material" rid="SD1">Fig.S2B</xref>) was sufficient to revert BCR dependency in resistant cells (<xref ref-type="fig" rid="F2">Fig 2E</xref>, right).</p></sec><sec id="S5"><title>ADARreg affects the sensitivity to ibrutinib</title><p id="P12">To confirm ADARreg function, we transduced Ibrutinib-resistant VL51 cells with constructs expressing mCherry and pgRNAs targeting the ADARreg TSS, and GFP-tagged dCas9ZIM3 (<xref ref-type="supplementary-material" rid="SD1">Fig.S2C</xref>). Dual fluorescent markers tracked ADARreg knockdown (eRNA_kd) cells within mixed populations for a competitive assay. We monitored double-positive cells over 10 days, comparing them to wild-type cells. The competition assay confirmed the CRISPRi screening results. ADARreg knockdown cells were more sensitive to ibrutinib than the wild-type and pgRNA-expressing cells, confirming transcriptional interference caused these effects (<xref ref-type="supplementary-material" rid="SD1">Fig.S2C</xref>).</p></sec><sec id="S6"><title>IncPCED1b validation as regulator of ibrutinib response</title><p id="P13">RP11-96H19.1 (ENSG00000257261), referred to as lncPCED1b due to its proximity to the <italic>PCED1b</italic> gene (<xref ref-type="supplementary-material" rid="SD1">Fig.S2B</xref>), was identified in the CRISPRi screen as promoting ibrutinib sensitivity in Ibrutinib-resistant VL51 cells and, to a lesser extent, in parental cells (<xref ref-type="fig" rid="F2">Fig.2E</xref>). Stable interference with lncPCED1b transcription in both cell types reduced cell survival in resistant cells respect with control cells transduced with pgRNAs targeting KLK12, a non-expressed gene in our model. (<xref ref-type="supplementary-material" rid="SD1">Fig.S2D</xref>).</p><p id="P14">After two weeks, double-positive cells were sorted and expanded to establish stable knockdown models. We confirmed that ADARreg or lncPCED1b knockdown enhanced sensitivity to BTK inhibition in Ibrutinib-resistant cells (<xref ref-type="supplementary-material" rid="SD1">Fig.S2E</xref>). However, parental cells with lncPCED1b knockdown did not retain the phenotype (<xref ref-type="supplementary-material" rid="SD1">Fig.S2E</xref>).</p></sec><sec id="S7"><title>ADARreg silencing affects A-to-I editing in intronic regions</title><p id="P15">Given ADARreg’s potential role in regulating A-to-I RNA editing [<xref ref-type="bibr" rid="R19">19</xref>], we analyzed the transcriptional variants between parental VL51 cells, Ibrutinib-resistant cells expressing KLK12 pgRNAs, and Ibrutinib-resistant cells with stable knockdowns of ADARreg or lncPCED1b. Using the RED-ML algorithm, we identified approximately 24,000 editing sites within Alu sequences and 13,000 outside them across all experimental conditions (<xref ref-type="supplementary-material" rid="SD1">Table S4</xref>).</p><p id="P16">Focusing on sequence-specific editing sites found in at least three samples, we discovered that 66% (n=1,857) occurred outside Alu sequences and 33% (n=952) within (<xref ref-type="fig" rid="F3">Fig.3A</xref>, left). Differential editing analysis identified 195 non-Alu and 86 Alu-specific editing sites in the resistant cells. Similar analyses comparing ibrutinib-resistant cells with ADARreg knockdown (n=85 non-Alu; n=14 Alu) or lncPCED1b knockdown (n=69 non-Alu; n=18 Alu) showed that elncRNA silencing primarily affected editing outside Alu regions (<xref ref-type="fig" rid="F3">Fig.3A</xref>, right).</p><p id="P17">We also examined the genomic distribution of editing sites. Approximately 30% occurred in the 3’UTR, 20% in exons (mostly synonymous variants), 15% as exonic missense variants, and 17% in introns (<xref ref-type="fig" rid="F3">Fig.3B</xref>). ADARreg and lncPCED1b knockdown notably affected the editing sites within introns (<xref ref-type="fig" rid="F3">Fig.3B</xref>).</p><p id="P18">In Ibrutinib-resistant cells, intronic editing was largely lost compared to parental cells (<xref ref-type="fig" rid="F3">Fig.3C</xref>, left). ADARreg knockdown reversed this trend, increasing intronic editing in protein-coding genes while decreasing in noncoding genes (<xref ref-type="fig" rid="F3">Fig.3C</xref>, middle). Similarly, lncPCED1b knockdown also increased intronic editing sites (<xref ref-type="fig" rid="F3">Fig.3C</xref>, right). Many of the editing sites restored by ADARreg knockdown were initially present in parental cells but lost in resistant cells (<xref ref-type="fig" rid="F3">Fig.3D</xref>), and the differentially edited transcripts were predominantly involved in immune and cancer-related pathways (<xref ref-type="supplementary-material" rid="SD1">Table S5</xref>).</p></sec><sec id="S8"><title>ADARreg affects the editing of ncRNAs involved in ibrutinib sensitivity</title><p id="P19">Using the MEME tool, we identified a consensus sequence in the elncRNAs expressed in our model (<xref ref-type="fig" rid="F4">Fig.4A</xref>), complementary with a portion of the Alu element (<xref ref-type="fig" rid="F4">Fig.4B</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S6</xref>). This sequence is prone to form a stable double-stranded RNA (dsRNA) structure (<xref ref-type="fig" rid="F4">Fig.4C</xref>). When analyzing the full set of SEs active in our model, no comparable consensus sequence with equal dsRNA-forming potential was identified (<xref ref-type="fig" rid="F4">Fig.4A</xref>, <xref ref-type="supplementary-material" rid="SD1">S3A</xref>). This suggested SE-transcribed regions were predisposed to editing. Indeed, several elncRNAs and lincRNAs included in the CRISPRi screen were differentially edited in resistant compared to parental cells (<xref ref-type="fig" rid="F4">Fig.4D</xref>). Of particular interest, 37 editing sites showed significant differential editing in the absence of ADARreg, most of which were more edited than the controls (<xref ref-type="fig" rid="F4">Fig.4D</xref>). lncPCED1b (RP11-96H19.1) was the third most edited ncRNA in ADARreg knockdown cells (<xref ref-type="fig" rid="F4">Fig.4D</xref>). Remarkably, lncPCED1b knockdown partially restored the parental editome in resistant cells (<xref ref-type="fig" rid="F4">Fig.4E</xref>). Additionally, a subset of differentially edited sites overlapped between lncPCED1b and ADARreg knockdown, suggesting that lncPCED1b mediates A-to-I editing regulated by ADARreg (<xref ref-type="fig" rid="F4">Fig.4F</xref>).</p><p id="P20">To further validate this, we analyzed parental cells with stable knockdowns of lncPCED1b or LINC00511, a known oncogene not associated with RNA editing. Editing sites altered by LINC00511 knockdown were less correlated with those involved in resistance than ADARreg knockdown (<xref ref-type="supplementary-material" rid="SD1">Fig.S3B-D</xref>). Notably, lncPCED1b knockdown did not similarly affect the editome of parental cells, where ADARreg expression was irrelevant for ibrutinib resistance (<xref ref-type="supplementary-material" rid="SD1">Fig.S3E</xref>). Furthermore, intronic editing events after lncPCED1b or LINC00511 knockdown were less pronounced in parental cells than in resistant ones (<xref ref-type="supplementary-material" rid="SD1">Fig.S3F, G</xref>).</p></sec><sec id="S9"><title>ADARreg modulates BTK inhibition by regulating ADAR2 activity</title><p id="P21">We tested ADARreg function in ibrutinib-resistant VL51 and Jeko1 cells. Jeko1, a mantle cell lymphoma (MCL) line, expressed ADARreg and showed low sensitivity to ibrutinib. Stable ADARreg silencing in both cell lines significantly increased their sensitivity to ibrutinib compared to cells expressing control KLK12-pgRNAs (<xref ref-type="fig" rid="F5">Fig.5 A, B</xref>, <xref ref-type="supplementary-material" rid="SD1">S4A</xref>).</p><p id="P22">To confirm that ADARreg <italic>per se</italic> contributed to drug resistance, we used antisense oligonucleotides to degrade ADARreg in Jeko1 cells. Electroporation with Locked Nucleic Acids (LNAs) targeting ADARreg reduced cell proliferation and increased sensitivity to ibrutinib (<xref ref-type="fig" rid="F5">Fig.5C</xref>).</p><p id="P23">We further tested ADARreg’s impact on drug sensitivity in HAIRM, an ibrutinib-sensitive cell line derived from MZL or hairy cell leukemia variant. As in Jeko1, we observed a reduction in cell viability four days after LNA electroporation (<xref ref-type="supplementary-material" rid="SD1">Fig.S4B</xref>). However, HAIRM did not exhibit permanent changes in proliferation or drug sensitivity (<xref ref-type="supplementary-material" rid="SD1">Fig S4C</xref>).</p><p id="P24">We also examined ADARreg expression in a cohort of MCL patients, where higher ADARreg expression correlated with poorer overall survival (<xref ref-type="fig" rid="F5">Fig.5D</xref>). ADARreg expression was negatively correlated with ADAR1 (<xref ref-type="fig" rid="F5">Fig.5E</xref>, top) and positively correlated with ADAR2 (coded by ADARB1) (<xref ref-type="fig" rid="F5">Fig.5E</xref>, bottom).</p><p id="P25">While ADARreg knockdown did not significantly alter ADAR transcription (<xref ref-type="supplementary-material" rid="SD1">Fig.S4D</xref>), it did shift the isoform ratio of ADARB1 in ibrutinib-resistant VL51 cells. Three ADARB1 isoforms upregulated during resistance were significantly repressed after ADARreg knockdown: ADARB1-214, which skips exon 7, resulting in a slightly longer protein (ADAR2b) with lower enzymatic activity, and two untranslated alternatively spliced transcripts (<xref ref-type="fig" rid="F5">Fig.5F</xref>)[<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R27">27</xref>].</p><p id="P26">Immunoblotting confirmed that ADARreg knockdown did not affect ADAR1 levels (<xref ref-type="supplementary-material" rid="SD1">Fig.S4E</xref>) or subcellular distribution (<xref ref-type="supplementary-material" rid="SD1">Fig.S4F</xref>). However, ADAR2 did not change in total level but showed increased nuclear translocation, likely enhancing intronic RNA editing (<xref ref-type="fig" rid="F5">Fig 5G</xref>, <xref ref-type="supplementary-material" rid="SD1">S5G</xref>). ADARreg was also mainly nuclear, in line with its putative role in regulating intronic editing (<xref ref-type="supplementary-material" rid="SD1">Fig.S4H</xref>).</p></sec><sec id="S10"><title>ADARreg and lncPCED1b maintain the BCR inactivation by altering RNA homeostasis</title><p id="P27">Transcriptomic analysis of the ibrutinib-resistant VL51 cells after ADARreg or lncPCED1b knockdown (<xref ref-type="supplementary-material" rid="SD1">Table S7</xref>) revealed significant enrichment of genesets related to the proteasome, spliceosome, and RNA degradation among the transcripts more expressed in resistant cells compared to parental cells (<xref ref-type="fig" rid="F6">Fig.6A</xref>). Inhibiting these elncRNAs, we also reversed genesets normally suppressed by BTK inhibition, in resistant cells, confirming the reactivation of BCR dependency (<xref ref-type="fig" rid="F6">Fig.6A</xref>). ADARreg and lncPCED1b inhibition reverted the SMZL signature associated with ibrutinib-resistance, confirming their role in maintaining the resistant phenotype (<xref ref-type="fig" rid="F6">Fig.6A</xref>). Furthermore, resistant cells had lower expression of genes involved in interferon response compared to parental cells. Still, ADARreg and lncPCED1b silencing reactivated immune responses through PRR signaling (<xref ref-type="fig" rid="F6">Fig.6A</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S8</xref>). Specifically, ADARreg knockdown restored the expression of interferon-stimulated genes (ISGs) such as IFIH1 and DHX58, which encode critical proteins in the RIG-I-like receptor (RLR) pathway that induces interferon production after detecting unedited dsRNA, normally suppressed by ADAR editing [<xref ref-type="bibr" rid="R26">26</xref>] (<xref ref-type="fig" rid="F6">Fig.6B</xref>).</p></sec><sec id="S11"><title>ADARreg modulates IRF3 activity</title><p id="P28">Since A-to-I RNA editing can influence transcript stability [<xref ref-type="bibr" rid="R28">28</xref>], we assessed post-transcriptional modulation of transcript abundance using exon-intron split analysis (EISA). Cells with ADARreg or lncPCED1b knockdown exhibited increased transcript stability, particularly ADARreg kd cells (106 stabilized transcripts compared to 64 for lncPCED1b) (<xref ref-type="fig" rid="F6">Fig.6C</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig.S5B</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S9</xref>). This aligned with reducing many enzymes involved in RNA degradation in our models. The stabilized transcripts were involved in metabolism pathways and viral infection response (<xref ref-type="fig" rid="F6">Fig.6D</xref>), while lncPCED1b knockdown primarily stabilized transcripts encoding proteasome components (<xref ref-type="supplementary-material" rid="SD1">Fig.S5B</xref>). Notably, IRF3, a key transcription factor in immune response, was post-transcriptionally regulated by ADARreg. ADARreg kd stabilized the isoform IRF3-203, encoding for the active IRF3, while destabilized IRF3-202, encoding for the dominant-negative IRF3a, which is retained in the cytoplasm (<xref ref-type="fig" rid="F6">Fig.6E</xref>, <xref ref-type="supplementary-material" rid="SD1">S5C</xref>) [<xref ref-type="bibr" rid="R29">29</xref>]. This shift in isoform balance was confirmed at the protein level (<xref ref-type="fig" rid="F6">Fig.6F</xref>, <xref ref-type="supplementary-material" rid="SD1">S5D</xref>), and immunofluorescence demonstrated increased nuclear localization of IRF3 after ADARreg knockdown (<xref ref-type="fig" rid="F6">Fig.6G</xref>, <xref ref-type="supplementary-material" rid="SD1">S5E</xref>). In resistant cells, ADARreg expression reduced all IRF3 transcripts, with the active IRF3-203 isoform completely depleted (<xref ref-type="fig" rid="F6">Fig.6E</xref>, <xref ref-type="supplementary-material" rid="SD1">S5C</xref>). After ADARreg knockdown, IRF3 target genes, typically downregulated in resistant cells, were reactivated (<xref ref-type="supplementary-material" rid="SD1">Fig.S5F</xref>).</p></sec><sec id="S12"><title>ADARreg alters STING and NF-kB signaling</title><p id="P29">The cGAS-STING pathway is a major regulator of IRF3 [<xref ref-type="bibr" rid="R30">30</xref>]. The ibrutinib-resistant VL51 cells upregulated STING but favored an alternative translation initiation (<xref ref-type="fig" rid="F7">Fig.7A</xref>), producing a dominant-negative STINGβ (encoded by STING1-216), which disrupts STING signaling [<xref ref-type="bibr" rid="R31">31</xref>]. ADARreg knockdown reverted the ratio between STING and STINGβ, restoring proper signaling (<xref ref-type="fig" rid="F7">Fig.7A</xref>). Indeed, the STING agonist diABZI (10 μM) enhanced BTK inhibition in resistant cells like ADARreg knockdown, which further increased the synergism between ibrutinib and STING agonist in ibrutinib-resistant cells (<xref ref-type="fig" rid="F7">Fig.7B</xref>). A similar mechanism propagated further downstream, with STING triggering NF-κB [<xref ref-type="bibr" rid="R30">30</xref>]. In resistant cells, ADARreg altered RELA transcription, producing an inactive N-terminal fragment of p65 (<xref ref-type="fig" rid="F7">Fig.7C</xref>). ADARreg knockdown restored the balance between active p65 and its inhibitory N-terminal fragment at both the RNA (<xref ref-type="fig" rid="F7">Fig.7C</xref>) and protein level (<xref ref-type="fig" rid="F7">Fig.7D</xref>, <xref ref-type="supplementary-material" rid="SD1">S6A</xref>). This event was translated into higher nuclear translocation of NF-κB after ADARreg knockdown (<xref ref-type="fig" rid="F7">Fig.7E</xref>). However, lncPCED1b knockdown only increased active p65 without affecting the inhibitory form, which explains its lesser nuclear NF-κB compared to ADARreg knockdown. (<xref ref-type="fig" rid="F7">Fig.7D</xref>). Similarly, the phosphorylation of full-length p65 after BCR stimulation increased in resistant cells after ADARreg but not after lncPCED1b knockdown (<xref ref-type="supplementary-material" rid="SD1">Fig.S6B</xref>).</p></sec><sec id="S13"><title>ADARreg alters transcript usage across key genes</title><p id="P30">We detected alternative transcripts in key genes as ADARB1 (<xref ref-type="fig" rid="F5">Fig.5F</xref>), IRF3 (<xref ref-type="fig" rid="F6">Fig.6E</xref>), STING (<xref ref-type="fig" rid="F7">Fig.7A</xref>) and RELA (<xref ref-type="fig" rid="F7">Fig.7C</xref>), so we investigated whether ADARreg knockdown generally affected transcript usage. Transcriptome analysis showed that ADARreg knockdown induced widespread alternative transcript usage, affecting 1,536 genes, while lncPCED1b knockdown altered only 469 genes (<xref ref-type="fig" rid="F7">Fig.7F</xref>, <xref ref-type="supplementary-material" rid="SD1">7S6C</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S10</xref>). Many of these isoform changes were linked to intronic editing, with ADARreg affecting 160 genes and lncPCED1b affecting 63 genes (<xref ref-type="supplementary-material" rid="SD1">Fig.7S6C</xref>). Nineteen of these genes were common to both and primarily involved in p53 regulation after DNA damage (<xref ref-type="supplementary-material" rid="SD1">Fig.S6 D, E</xref>). Variations in 3’UTR editing were rarely associated with isoform changes (<xref ref-type="fig" rid="F7">Fig 7F</xref>). Some genes with sequence-specific editing, ENO1, RPS3, CLEC2D, MFN1, and AUTS2, showed alternative transcript usage after ADARreg knockdown, with RPS3 being similarly affected by lncPCED1b knockdown (<xref ref-type="fig" rid="F7">Fig.7F</xref>, <xref ref-type="supplementary-material" rid="SD1">7S6C</xref>). Ribosomal protein S3 <italic>(rpS3),</italic> a multifunctional protein involved in translation, DNA repair, apoptosis, and immune regulation, interacts with p65 to activate specific genes [<xref ref-type="bibr" rid="R33">33</xref>]. The expression of the N-terminal fragment of p65 inhibits the RPS3-specific signature [<xref ref-type="bibr" rid="R28">28</xref>]. RPS3 has different domains responsible for apoptosis and DNA damage (<xref ref-type="fig" rid="F7">Fig.7G</xref>)[<xref ref-type="bibr" rid="R34">34</xref>]. ADARreg and lncPCED1b knockdown restored expression of the RPS3-208 isoform, which was absent in resistant cells (<xref ref-type="fig" rid="F7">Fig.7H</xref>). This isoform lacks the DNA repair domain but retains the apoptosis-inducing and p65-interacting domains (<xref ref-type="fig" rid="F7">Fig.7G</xref>).</p></sec><sec id="S14"><title>ADARreg inhibits NK cell-mediated cytotoxicity</title><p id="P31">ADARreg knockdown modulated the isoforms of LLT1 (encoded by <italic>CLEC2D</italic> gene), a ligand for the CD161 (NKR-P1A) receptor expressed on NK and T cells [<xref ref-type="bibr" rid="R35">35</xref>, <xref ref-type="bibr" rid="R36">36</xref>] (<xref ref-type="fig" rid="F7">Fig.7I</xref>). Along with the modulation of IRF3, this suggested that ADARreg knockdown could increase NK cell-mediated killing of resistant cells. Co-culturing ADARreg knockdown VL51 cells with NK cells from a healthy donor resulted in significantly higher NK cell-mediated killing than control cells (<xref ref-type="fig" rid="F8">Fig.8A</xref>, <xref ref-type="supplementary-material" rid="SD1">S7A</xref>). Additionally, NK cells survived longer in co-cultures with ADARreg knockdown cells (<xref ref-type="supplementary-material" rid="SD1">Fig.S7B</xref>).</p><p id="P32">To validate these findings, we used publicly available single-cell RNA seq of four chronic lymphocytic leukemia (CLL) patients undergoing ibrutinib treatment [<xref ref-type="bibr" rid="R37">37</xref>]to validate these findings. Using genes altered by stable ADARreg kd as a surrogate for ADARreg level (undetectable in polyA datasets), we compared CLL cells from two fast and two slow responders (<xref ref-type="supplementary-material" rid="SD1">Fig.S7C</xref>). Transcriptomic profiles of surviving cells after treatment resembled the SMZL ADARreg<sup>high</sup>-resistant model (<xref ref-type="supplementary-material" rid="SD1">Fig.S7C</xref>). Similar cells were also more abundant at pretreatment time point in slow responders (<xref ref-type="supplementary-material" rid="SD1">Fig.S7C</xref>). We analyzed NK cells in untreated samples, annotating them as cytotoxic, inflammatory, or tumor-associated NK (TANK) cells (<xref ref-type="supplementary-material" rid="SD1">Fig.S7D</xref>) [<xref ref-type="bibr" rid="R38">38</xref>], and analyzed cell-cell communication using CellChat (<xref ref-type="fig" rid="F8">Fig.8B</xref>, <xref ref-type="supplementary-material" rid="SD1">S8</xref>). At pretreatment, in a slow responder, ADARreg<sup>high</sup>-like B cells increased CLEC2D-CD161 interactions with active NKs, compared to ADARreg<sup>low</sup>-like B cells (<xref ref-type="fig" rid="F8">Fig.8B</xref>). Conversely, ADARreg<sup>low</sup>-like B cells interacted more with TANK cells through CD99-PILRA signaling, recently associated with favorable immunotherapy outcomes [<xref ref-type="bibr" rid="R39">39</xref>] (<xref ref-type="fig" rid="F8">Fig.8B</xref>). No differences in cell communication between ADARreg <sup>high/low</sup>-like B and NK cells were significant in the fast responder (<xref ref-type="supplementary-material" rid="SD1">Fig. S8</xref>). Tumor cells persisting after treatment had higher CLEC2D expression and ADARreg signature in both patients (<xref ref-type="fig" rid="F8">Fig.8C</xref>). However, those cells were more abundant in slow than fast responder (<xref ref-type="fig" rid="F8">Fig.8C</xref>). In summary, ADARreg modulated CLEC2D isoform balance, favoring NK inhibition in IBR-resistant cells in vitro. A transcriptional program like the one controlled by ADARreg linked high CLEC2D expression to ibrutinib-resistance in CLL patients.</p></sec><sec id="S15" sec-type="discussion"><title>Discussion</title><p id="P33">This study demonstrated that LOC730338, which we renamed ADARreg, can affect the sensitivity to the BTK inhibitor ibrutinib and play a key role in maintaining immune suppression in lymphoma cells. We linked ADARreg to the regulation of the inflammatory response at multiple levels. ADARreg repressed IRF3 transcriptionally and post-transcriptionally. It reduced A-to-I editing of intronic regions, affecting the alternative splicing of genes that stimulate an innate immune response. Without ADARreg, the BCR signaling was reactivated, making the B cells more likely to be killed by NK cells.</p><p id="P34">In the presence of pathogens, PRRs activate pathways such as NF-κB, MAPK, and type-I interferon [<xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R41">41</xref>]. This response must be tightly regulated to prevent overactivation without a real need [<xref ref-type="bibr" rid="R35">35</xref>]. ADAR1 and ADAR2, through A-to-I RNA editing, play a central role in preventing excessive immune activation by editing self-dsRNA [<xref ref-type="bibr" rid="R42">42</xref>]. They also restrain the inflammatory response, modulating the stability and alternative splicing of transcripts mainly involved in antiviral response[<xref ref-type="bibr" rid="R43">43</xref>]. Indeed, A-to-I editing can drastically alter RNA’s structural and coding properties [<xref ref-type="bibr" rid="R44">44</xref>]. In detail, A-to-I editing by ADAR2 can convert an intronic AA dinucleotide into an AI dinucleotide that can act like the canonical AG 3’ splice site acceptor, impacting splicing events [<xref ref-type="bibr" rid="R45">45</xref>]. Our findings add a new layer of complexity to this regulatory network, as we observed significant alterations in these mechanisms following ADARreg knockdown. Splicing was strongly impaired by ADARreg knockdown that reduced the expression of many genes, such as DHX8, DDX42, SF3B1, or PUS7.</p><p id="P35">Although ADARreg was previously associated with RNA editing, its exact role remained unclear [<xref ref-type="bibr" rid="R19">19</xref>]. We showed that silencing ADARreg disrupts RNA editing, not by directly regulating ADAR expression, but by possibly changing the intracellular distribution and target interactions of ADARs, particularly ADAR2. The latter, a less abundant but more sequence-specific editor than ADAR1, was most affected by ADARreg knockdown. This led to impaired editing, especially outside repetitive Alu sequences, in line with an ADAR2-dependent mechanism [<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R27">27</xref>]. We hypothesize that ADARreg limits ADAR2’s ability to edit introns, influencing alternative transcript usage.</p><p id="P36">Alternative splicing is a critical regulatory mechanism in genes involved in innate immunity, such as cGAS, STING, TBK, and IRF3 [<xref ref-type="bibr" rid="R31">31</xref>, <xref ref-type="bibr" rid="R47">47</xref>, <xref ref-type="bibr" rid="R48">48</xref>]. We observed that ADARreg knockdown altered the splicing of STING and IRF3, which are key components of immune signaling. More broadly, ADARreg impacted the alternative splicing of many genes involved in DNA damage repair, supporting its broader role in maintaining RNA homeostasis in resistant cells.</p><p id="P37">ADAR2 has previously been proposed as a potential tumor suppressor in glioma [<xref ref-type="bibr" rid="R49">49</xref>], and cancer often takes advantage of alternative splicing to promote the expression of pro-tumorigenic isoforms [<xref ref-type="bibr" rid="R45">45</xref>, <xref ref-type="bibr" rid="R50">50</xref>]. Furthermore, tumor cells, which often release fragmented DNA, can evade immune detection by dampening DNA damage-associated molecular patterns (DAMPs), decreasing antitumoral immune attacks. ADARreg may contribute to this immune evasion mechanism by modulating alternative splicing and inhibiting interferon responses.</p><p id="P38">In addition to the alternative transcript usage of IRF3 and STING, ADARreg affected immune signaling by regulating the NF-κB signaling. We observed the production of an alternative form of p65, which retains the ribosomal protein RPS3 in the cytoplasm. RPS3, beyond its ribosomal functions, is involved in apoptosis, DNA repair, and transcriptional regulation [<xref ref-type="bibr" rid="R51">51</xref>]. RPS3 was identified as a non-Rel subunit of NF-κB [<xref ref-type="bibr" rid="R33">33</xref>] and has already been reported to be involved in cell proliferation and drug resistance in multiple myeloma [<xref ref-type="bibr" rid="R52">52</xref>]. RPS3 was our model’s most heavily edited and alternatively spliced gene under ADARreg control. The precise role of RPS3 in SMZL growth and BCR pathway activation remains to be elucidated.</p><p id="P39">Our findings suggest that ADARreg works within a broader epigenetic network of ncRNAs that regulate intronic editing and alternative transcript usage. lncPCED1b knockdown showed similar effects, mirroring ADARreg’s influence on transcriptomic alterations. ADARreg also regulates the editing of relevant ncRNAs, including lncPCED1b. It is possible that lncPCED1b, like others, might be a mediator of ADARreg action. This is consistent with recent findings linking elncRNA splicing to enhancer activity[<xref ref-type="bibr" rid="R41">41</xref>]. We propose that ADARreg, modulating ADAR2 accessibility to subsets of elncRNAs, depending on the presence of a consensus sequence, can regulate their processing and, in turn, the balance of protumoral transcriptional isoforms.</p><p id="P40">ADARreg silencing reactivates the INF-I response and modulates surface receptors such as LLT1, increasing SMZL cells’ immunogenicity and susceptibility to NK cell-mediated cytotoxicity. In SMZL patients, poorer outcomes are associated with an immune-suppressive phenotype with immune checkpoint activation [<xref ref-type="bibr" rid="R53">53</xref>]. These patients often exhibit KLF2 and NOTCH2 mutations, but a clear mechanism for immune escape is missing. ADARreg may be a critical factor influencing tumor-microenvironment interactions.</p><p id="P41">This mechanism was further validated in CLL patients, where we observed a link between the selection of tumor clones resistant to BCR inhibition and the suppression of an immunological signature modulated by ADARreg. Moreover, an ADARreg<sup>high</sup>-signature in hematological tumors, such as MZL, CLL, and MCL, may indicate an unfavorable prognosis for patients treated with BCR signaling inhibitors. Conversely, ADARreg represents a promising therapeutic target for antisense oligonucleotide strategies to elicit spontaneous immune responses against immune-suppressive cells.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>supplementary materials</label><media xlink:href="EMS202033-supplement-supplementary_materials.pdf" mimetype="application" mime-subtype="pdf" id="d38aAcEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Table S1</label><media xlink:href="EMS202033-supplement-Table_S1.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d38aAcEcB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>Table S2</label><media xlink:href="EMS202033-supplement-Table_S2.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d38aAcEdB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><label>Table S3</label><media xlink:href="EMS202033-supplement-Table_S3.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d38aAcEeB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD5"><label>Table S4</label><media xlink:href="EMS202033-supplement-Table_S4.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d38aAcEfB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD6"><label>Table S5</label><media xlink:href="EMS202033-supplement-Table_S5.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d38aAcEgB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD7"><label>Table S6</label><media xlink:href="EMS202033-supplement-Table_S6.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d38aAcEhB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD8"><label>Table S7</label><media xlink:href="EMS202033-supplement-Table_S7.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d38aAcEiB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD9"><label>Table S8</label><media xlink:href="EMS202033-supplement-Table_S8.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d38aAcEjB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD10"><label>Table S9</label><media xlink:href="EMS202033-supplement-Table_S9.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d38aAcEkB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD11"><label>Table S10</label><media xlink:href="EMS202033-supplement-Table_S10.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d38aAcElB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD12"><label>Table S11</label><media xlink:href="EMS202033-supplement-Table_S11.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d38aAcEmB" position="anchor"/></supplementary-material></sec></body><back><ack id="S16"><title>Funding</title><p>This work was partially supported by the Swiss National Science Foundation grants CRSK-3_190808, SNSF 310030_197466, and SNSF 31003A_163232/1). NM was supported by a Ph.D. Fellowship of the NCCR RNA &amp; Disease, a National Center of Competence in Research funded by the Swiss National Science Foundation (grant numbers 182880 and 205601). SR was funded by Science Foundation Ireland under Grant number [18/CRT/6214] and in part by the EU’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant H2020-MSCA-COFUND-2019-945385.</p></ack><fn-group><fn id="FN1" fn-type="conflict"><p id="P42"><bold>Disclosure of Potential Conflicts of Interest</bold></p><p id="P43">Luciano Cascione: institutional research funds from Orion; travel grant from HTG. Alberto J. Arribas: travel grant from Astra Zeneca, consultant for PentixaPharm. Chiara Tarantelli: travel grant from iOnctura. Francesco Bertoni: institutional research funds from ADC Therapeutics, Bayer AG, BeiGene, Floratek Pharma, Helsinn, HTG Molecular Diagnostics, Ideogen AG, Idorsia Pharmaceuticals Ltd., Immagene, ImmunoGen, Menarini Ricerche, Nordic Nanovector ASA, Oncternal Therapeutics, Spexis AG; consultancy fee from BIMINI Biotech, Helsinn, Menarini; advisory board fees to institution from Novartis; expert statements provided to HTG Molecular Diagnostics; travel grants from Amgen, Astra Zeneca, Beigene, InnoCare, iOnctura. The other Authors have nothing to disclose.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>D</given-names></name><name><surname>Bertoni</surname><given-names>F</given-names></name><name><surname>Zucca</surname><given-names>E</given-names></name></person-group><article-title>Marginal-Zone Lymphomas</article-title><source>N Engl J Med</source><year>2022</year><volume>386</volume><issue>6</issue><fpage>568</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">35139275</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petro</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Bruton’s tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement</article-title><source>J Exp Med</source><year>2000</year><volume>191</volume><issue>10</issue><fpage>1745</fpage><lpage>54</lpage><pub-id pub-id-type="pmcid">PMC2193161</pub-id><pub-id pub-id-type="pmid">10811867</pub-id><pub-id pub-id-type="doi">10.1084/jem.191.10.1745</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanchina</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia</article-title><source>Nat Rev Clin Oncol</source><year>2024</year><volume>21</volume><issue>12</issue><fpage>867</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">39487228</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noy</surname><given-names>A</given-names></name><etal/></person-group><article-title>Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma</article-title><source>Blood</source><year>2017</year><volume>129</volume><issue>16</issue><fpage>2224</fpage><lpage>2232</lpage><pub-id pub-id-type="pmcid">PMC5399483</pub-id><pub-id pub-id-type="pmid">28167659</pub-id><pub-id pub-id-type="doi">10.1182/blood-2016-10-747345</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opat</surname><given-names>S</given-names></name><etal/></person-group><article-title>The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma</article-title><source>Clin Cancer Res</source><year>2021</year><volume>27</volume><issue>23</issue><fpage>6323</fpage><lpage>6332</lpage><pub-id pub-id-type="pmcid">PMC9401507</pub-id><pub-id pub-id-type="pmid">34526366</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-1704</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L</given-names></name><etal/></person-group><article-title>Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study</article-title><source>Am J Hematol</source><year>2023</year><volume>98</volume><issue>11</issue><fpage>1742</fpage><lpage>1750</lpage><pub-id pub-id-type="pmid">37647123</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>DM</given-names></name><name><surname>Byrd</surname><given-names>JC</given-names></name></person-group><article-title>Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies</article-title><source>Blood</source><year>2021</year><volume>138</volume><issue>13</issue><fpage>1099</fpage><lpage>1109</lpage><pub-id pub-id-type="pmcid">PMC8570054</pub-id><pub-id pub-id-type="pmid">34320163</pub-id><pub-id pub-id-type="doi">10.1182/blood.2020006783</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma</article-title><source>Hematol Oncol</source><year>2021</year><volume>39</volume><issue>5</issue><fpage>605</fpage><lpage>615</lpage><pub-id pub-id-type="pmcid">PMC9293416</pub-id><pub-id pub-id-type="pmid">34651869</pub-id><pub-id pub-id-type="doi">10.1002/hon.2933</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaffer</surname><given-names>AL</given-names><suffix>3rd</suffix></name><etal/></person-group><article-title>Overcoming Acquired Epigenetic Resistance to BTK Inhibitors</article-title><source>Blood Cancer Discov</source><year>2021</year><volume>2</volume><issue>6</issue><fpage>630</fpage><lpage>647</lpage><pub-id pub-id-type="pmcid">PMC8580621</pub-id><pub-id pub-id-type="pmid">34778802</pub-id><pub-id pub-id-type="doi">10.1158/2643-3230.BCD-21-0063</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma</article-title><source>Cell Rep</source><year>2021</year><volume>34</volume><issue>11</issue><elocation-id>108870</elocation-id><pub-id pub-id-type="pmcid">PMC8057695</pub-id><pub-id pub-id-type="pmid">33730585</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108870</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arribas</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Resistance to PI3Kdelta inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis</article-title><source>Haematologica</source><year>2022</year><volume>107</volume><issue>11</issue><fpage>2685</fpage><lpage>2697</lpage><pub-id pub-id-type="pmcid">PMC9614536</pub-id><pub-id pub-id-type="pmid">35484662</pub-id><pub-id pub-id-type="doi">10.3324/haematol.2021.279957</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arribas</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms</article-title><source>Mol Cancer Ther</source><year>2024</year><volume>23</volume><issue>3</issue><fpage>368</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">38052765</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattick</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Long non-coding RNAs: definitions, functions, challenges and recommendations</article-title><source>Nat Rev Mol Cell Biol</source><year>2023</year><volume>24</volume><issue>6</issue><fpage>430</fpage><lpage>447</lpage><pub-id pub-id-type="pmcid">PMC10213152</pub-id><pub-id pub-id-type="pmid">36596869</pub-id><pub-id pub-id-type="doi">10.1038/s41580-022-00566-8</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>R</given-names></name><etal/></person-group><article-title>An atlas of active enhancers across human cell types and tissues</article-title><source>Nature</source><year>2014</year><volume>507</volume><issue>7493</issue><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="pmcid">PMC5215096</pub-id><pub-id pub-id-type="pmid">24670763</pub-id><pub-id pub-id-type="doi">10.1038/nature12787</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>F</given-names></name><etal/></person-group><article-title>Activating RNAs associate with Mediator to enhance chromatin architecture and transcription</article-title><source>Nature</source><year>2013</year><volume>494</volume><issue>7438</issue><fpage>497</fpage><lpage>501</lpage><pub-id pub-id-type="pmcid">PMC4109059</pub-id><pub-id pub-id-type="pmid">23417068</pub-id><pub-id pub-id-type="doi">10.1038/nature11884</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>D</given-names></name><etal/></person-group><article-title>Enhancer switching in cell lineage priming is linked to eRNA, Brg1 ‘s AT-hook, and SWI/SNFrecruitment</article-title><source>Mol Cell</source><year>2024</year><volume>84</volume><issue>10</issue><fpage>1855</fpage><lpage>1869</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="pmcid">PMC11104297</pub-id><pub-id pub-id-type="pmid">38593804</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2024.03.013</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agirre</surname><given-names>X</given-names></name><etal/></person-group><article-title>Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>821</fpage><pub-id pub-id-type="pmcid">PMC6379396</pub-id><pub-id pub-id-type="pmid">30778059</pub-id><pub-id pub-id-type="doi">10.1038/s41467-019-08679-z</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napoli</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma</article-title><source>Haematologica</source><year>2022</year><volume>107</volume><issue>5</issue><fpage>1131</fpage><lpage>1143</lpage><pub-id pub-id-type="pmcid">PMC9052922</pub-id><pub-id pub-id-type="pmid">34162177</pub-id><pub-id pub-id-type="doi">10.3324/haematol.2020.267096</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giacopuzzi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Genome-wide analysis of consistently RNA edited sites in human blood reveals interactions with mRNA processing genes and suggests correlations with cell types and biological variables</article-title><source>BMC Genomics</source><year>2018</year><volume>19</volume><issue>1</issue><fpage>963</fpage><pub-id pub-id-type="pmcid">PMC6307200</pub-id><pub-id pub-id-type="pmid">30587120</pub-id><pub-id pub-id-type="doi">10.1186/s12864-018-5364-8</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inokuchi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Establishment and characterization of a villous lymphoma cell line from splenic B-cell lymphoma</article-title><source>Leuk Res</source><year>1995</year><volume>19</volume><issue>11</issue><fpage>817</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">8551798</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arribas</surname><given-names>A</given-names></name><etal/></person-group><article-title>IL16 PRODUCTION IS A MECHANISM OF RESISTANCE TO BTK INHIBITORS AND TO R-CHOP</article-title><source>Hematological Oncology</source><year>2023</year><volume>41</volume><issue>S2</issue><fpage>188</fpage><lpage>189</lpage></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Pan-Yun Ting</surname><given-names>J</given-names></name></person-group><article-title>Holding the inflammatory system in check: NLRs keep it cool</article-title><source>F1000Prime Rep</source><year>2015</year><volume>7</volume><fpage>15</fpage><pub-id pub-id-type="pmcid">PMC4335796</pub-id><pub-id pub-id-type="pmid">25750733</pub-id><pub-id pub-id-type="doi">10.12703/P7-15</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whyte</surname><given-names>WA</given-names></name><etal/></person-group><article-title>Master transcription factors and mediator establish super-enhancers at key cell identity genes</article-title><source>Cell</source><year>2013</year><volume>153</volume><issue>2</issue><fpage>307</fpage><lpage>19</lpage><pub-id pub-id-type="pmcid">PMC3653129</pub-id><pub-id pub-id-type="pmid">23582322</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.035</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Consortium</surname><given-names>F</given-names></name><etal/></person-group><article-title>A promoter-level mammalian expression atlas</article-title><source>Nature</source><year>2014</year><volume>507</volume><issue>7493</issue><fpage>462</fpage><lpage>70</lpage><pub-id pub-id-type="pmcid">PMC4529748</pub-id><pub-id pub-id-type="pmid">24670764</pub-id><pub-id pub-id-type="doi">10.1038/nature13182</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alerasool</surname><given-names>N</given-names></name><etal/></person-group><article-title>An efficient KRAB domain for CRISPRi applications in human cells</article-title><source>Nat Methods</source><year>2020</year><volume>17</volume><issue>11</issue><fpage>1093</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">33020655</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinigaglia</surname><given-names>K</given-names></name><etal/></person-group><article-title>ADAR RNA editing in innate immune response phasing, in circadian clocks and in sleep</article-title><source>Biochim Biophys Acta Gene Regul Mech</source><year>2019</year><volume>1862</volume><issue>3</issue><fpage>356</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">30391332</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajji</surname><given-names>K</given-names></name><etal/></person-group><article-title>ADAR2 enzymes: efficient site-specific RNA editors with gene therapy aspirations</article-title><source>RNA</source><year>2022</year><volume>28</volume><issue>10</issue><fpage>1281</fpage><lpage>1297</lpage><pub-id pub-id-type="pmcid">PMC9479739</pub-id><pub-id pub-id-type="pmid">35863867</pub-id><pub-id pub-id-type="doi">10.1261/rna.079266.122</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brummer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Structure-mediated modulation of mRNA abundance by A-to-I editing</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><issue>1</issue><elocation-id>1255</elocation-id><pub-id pub-id-type="pmcid">PMC5665907</pub-id><pub-id pub-id-type="pmid">29093448</pub-id><pub-id pub-id-type="doi">10.1038/s41467-017-01459-7</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Interferon regulatory factor 3-CL, an isoform of IRF3, antagonizes activity of IRF3</article-title><source>Cell Mol Immunol</source><year>2011</year><volume>8</volume><issue>1</issue><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="pmcid">PMC4002990</pub-id><pub-id pub-id-type="pmid">21200386</pub-id><pub-id pub-id-type="doi">10.1038/cmi.2010.55</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yum</surname><given-names>S</given-names></name><etal/></person-group><article-title>TBK1 recruitment to STING activates both IRF3 and NF-kappaB that mediate immune defense against tumors and viral infections</article-title><source>Proc Natl Acad Sci U S A</source><year>2021</year><volume>118</volume><issue>14</issue><pub-id pub-id-type="pmcid">PMC8040795</pub-id><pub-id pub-id-type="pmid">33785602</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2100225118</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>J</given-names></name><etal/></person-group><article-title>The Alternatively Spliced Isoforms of Key Molecules in the cGAS-STING Signaling Pathway</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><elocation-id>771744</elocation-id><pub-id pub-id-type="pmcid">PMC8636596</pub-id><pub-id pub-id-type="pmid">34868032</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.771744</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Hardwidge</surname><given-names>PR</given-names></name></person-group><article-title>Ribosomal protein s3: a multifunctional target of attaching/effacing bacterial pathogens</article-title><source>Front Microbiol</source><year>2011</year><volume>2</volume><fpage>137</fpage><pub-id pub-id-type="pmcid">PMC3125523</pub-id><pub-id pub-id-type="pmid">21738525</pub-id><pub-id pub-id-type="doi">10.3389/fmicb.2011.00137</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>F</given-names></name><etal/></person-group><article-title>Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation</article-title><source>Cell</source><year>2007</year><volume>131</volume><issue>5</issue><fpage>927</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">18045535</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>CY</given-names></name>, J.<name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name></person-group><article-title>RpS3, a DNA repair endonuclease and ribosomal protein, is involved in apoptosis</article-title><source>FEBS Lett</source><year>2004</year><volume>560</volume><issue>1-3</issue><fpage>81</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">14988002</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braud</surname><given-names>VM</given-names></name><etal/></person-group><article-title>LLT1-CD161 Interaction in Cancer: Promises and Challenges</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><elocation-id>847576</elocation-id><pub-id pub-id-type="pmcid">PMC8854185</pub-id><pub-id pub-id-type="pmid">35185935</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.847576</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germain</surname><given-names>C</given-names></name><etal/></person-group><article-title>Characterization of alternatively spliced transcript variants of CLEC2D gene</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><issue>46</issue><fpage>36207</fpage><lpage>15</lpage><pub-id pub-id-type="pmcid">PMC2975243</pub-id><pub-id pub-id-type="pmid">20843815</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M110.179622</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rendeiro</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>577</fpage><pub-id pub-id-type="pmcid">PMC6989523</pub-id><pub-id pub-id-type="pmid">31996669</pub-id><pub-id pub-id-type="doi">10.1038/s41467-019-14081-6</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>F</given-names></name><etal/></person-group><article-title>A pan-cancer single-cell panorama of human natural killer cells</article-title><source>Cell</source><year>2023</year><volume>186</volume><issue>19</issue><fpage>4235</fpage><lpage>4251</lpage><elocation-id>e20</elocation-id><pub-id pub-id-type="pmid">37607536</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Comprehensive analysis of PILRAlpha’s association with the prognosis, tumor immune infiltration, and immunotherapy in pan-cancer</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><issue>1</issue><elocation-id>14334</elocation-id><pub-id pub-id-type="pmcid">PMC10471747</pub-id><pub-id pub-id-type="pmid">37652967</pub-id><pub-id pub-id-type="doi">10.1038/s41598-023-41649-6</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanng</surname><given-names>KRB</given-names></name><name><surname>Lauridsen</surname><given-names>EL</given-names></name><name><surname>Jakobsen</surname><given-names>MR</given-names></name></person-group><article-title>The balance of STING signaling orchestrates immunity in cancer</article-title><source>Nat Immunol</source><year>2024</year><volume>25</volume><issue>7</issue><fpage>1144</fpage><lpage>1157</lpage><pub-id pub-id-type="pmid">38918609</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>JY</given-names></name><name><surname>Marques</surname><given-names>AC</given-names></name></person-group><article-title>The activity of human enhancers is modulated by the splicing of their associated lncRNAs</article-title><source>PLoS Comput Biol</source><year>2022</year><volume>18</volume><issue>1</issue><elocation-id>e1009722</elocation-id><pub-id pub-id-type="pmcid">PMC8803168</pub-id><pub-id pub-id-type="pmid">35015755</pub-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1009722</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group><article-title>RNA editing underlies genetic risk of common inflammatory diseases</article-title><source>Nature</source><year>2022</year><volume>608</volume><issue>7923</issue><fpage>569</fpage><lpage>577</lpage><pub-id pub-id-type="pmcid">PMC9790998</pub-id><pub-id pub-id-type="pmid">35922514</pub-id><pub-id pub-id-type="doi">10.1038/s41586-022-05052-x</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>IX</given-names></name><etal/></person-group><article-title>ADAR regulates RNA editing, transcript stability, and gene expression</article-title><source>Cell Rep</source><year>2013</year><volume>5</volume><issue>3</issue><fpage>849</fpage><lpage>60</lpage><pub-id pub-id-type="pmcid">PMC3935819</pub-id><pub-id pub-id-type="pmid">24183664</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2013.10.002</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shevchenko</surname><given-names>G</given-names></name><name><surname>Morris</surname><given-names>KV</given-names></name></person-group><article-title>All I’s on the RADAR: role of ADAR in gene regulation</article-title><source>FEBS Lett</source><year>2018</year><volume>592</volume><issue>17</issue><fpage>2860</fpage><lpage>2873</lpage><pub-id pub-id-type="pmcid">PMC6327961</pub-id><pub-id pub-id-type="pmid">29770436</pub-id><pub-id pub-id-type="doi">10.1002/1873-3468.13093</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>799</fpage><pub-id pub-id-type="pmcid">PMC7005744</pub-id><pub-id pub-id-type="pmid">32034135</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-14621-5</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>NM</given-names></name><etal/></person-group><article-title>Pseudouridine synthases modify human pre-mRNA co-transcriptionally and affect pre-mRNA processing</article-title><source>Mol Cell</source><year>2022</year><volume>82</volume><issue>3</issue><fpage>645</fpage><lpage>659</lpage><elocation-id>e9</elocation-id><pub-id pub-id-type="pmcid">PMC8859966</pub-id><pub-id pub-id-type="pmid">35051350</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2021.12.023</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Identification of novel alternative splicing variants of interferon regulatory factor 3</article-title><source>Biochim Biophys Acta</source><year>2011</year><volume>1809</volume><issue>3</issue><fpage>166</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">21281747</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>FFY</given-names></name><name><surname>Alper</surname><given-names>S</given-names></name></person-group><article-title>Alternative pre-mRNA splicing as a mechanism for terminating Toll-like Receptor signaling</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><elocation-id>1023567</elocation-id><pub-id pub-id-type="pmcid">PMC9755862</pub-id><pub-id pub-id-type="pmid">36531997</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1023567</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Aberrant alternative splicing pattern of ADAR2 downregulates adenosine-to-inosine editing in glioma</article-title><source>Oncol Rep</source><year>2015</year><volume>33</volume><issue>6</issue><fpage>2845</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">25873329</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sciarrillo</surname><given-names>R</given-names></name><etal/></person-group><article-title>The role of alternative splicing in cancer: From oncogenesis to drug resistance</article-title><source>Drug Resist Updat</source><year>2020</year><volume>53</volume><elocation-id>100728</elocation-id><pub-id pub-id-type="pmid">33070093</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wier</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Identification of an N-terminal truncation of the NF-kappaB p65 subunit that specifically modulates ribosomal protein S3-dependent NF-kappaB gene expression</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><issue>51</issue><fpage>43019</fpage><lpage>29</lpage><pub-id pub-id-type="pmcid">PMC3522296</pub-id><pub-id pub-id-type="pmid">23115242</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M112.388694</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><etal/></person-group><article-title>Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma</article-title><source>Haematologica</source><year>2024</year><volume>109</volume><issue>4</issue><fpage>1206</fpage><lpage>1219</lpage><pub-id pub-id-type="pmcid">PMC10985453</pub-id><pub-id pub-id-type="pmid">37767568</pub-id><pub-id pub-id-type="doi">10.3324/haematol.2023.282789</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonfiglio</surname><given-names>F</given-names></name><etal/></person-group><article-title>Genetic and phenotypic attributes of splenic marginal zone lymphoma</article-title><source>Blood</source><year>2022</year><volume>139</volume><issue>5</issue><fpage>732</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">34653238</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Ibrutinib-resistance is associated with changes in super-enhancer activation</title><p><bold>(A)</bold> ChIP-seq H3k27 acetylated peak counts in three independent biological replicates of parental VL51 and ibrutinib-resistant (IBRr) derivatives. The horizontal bars show the number of total peaks in each sample. The red and green bars highlight the number of robust peaks differentially enriched in parental and ibrutinib-resistant cells. The number of <italic>bona fide</italic> enhancers is also indicated based on the co-occurrence of H3K4me1 peak and the absence of H3K4me3.</p><p><bold>(B)</bold> Schematic representation of an example of enhancer lost in ibrutinib-resistant cells, close to CDKN2A and CDKN2B loci. H3K4me1, H3K4me3, and input tracks are overlays of parental (green) and ibrutinib-resistant derivatives (red) replicates. Genomic positions of acetylated H3 peaks and transcripts differentially expressed (red blocks) in ibrutinib-resistant versus parental cells are indicated.</p><p><bold>(C)</bold> Volcano plot representing the expression of genes mapping within 40kb from an enhancer lost (left) or gained (right) in ibrutinib-resistant cells. Orange dots represent genes significantly downregulated, and green dots represent genes upregulated. The gene symbol of selected interesting genes is displayed.</p></caption><graphic xlink:href="EMS202033-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Functional screening of elncRNAs linked to BCR blockade</title><p><bold>(A)</bold> CRISPRi schematic representation.</p><p><bold>(B)</bold> Composition of CRISPRi lentiviral library, in terms of the constructs targeting different subtypes of controls and target genes.</p><p><bold>(C)</bold> Schematic overview of the CRISPRi screen experimental plan.</p><p><bold>(D)</bold> MDS plots showing the distribution of samples at the beginning of CRISPRi screen (T0, squared labels) or after 6 (T6), 10 (T10) or 14 (T14) days, based on the drop out of elncRNAs. Parental cells are represented in green, ibrutinib-resistant in red. Samples exposed to the drug are labelled with triangle, to the vehicle with the circle. The blue circle highlights the clustering of resistant cells, exposed to ibrutinib.</p><p><bold>(E)</bold> Scatter plot of β values measuring the drop out of single lincRNAs, left, or elncRNAs, right, in parental cells exposed to ibrutinib for 14 days respect to ibrutinib resistant cells. If the measurement is statistically significant (FDR&lt;0.2) the label with gene symbol is displayed. The bold black label indicates elncRNAs selected for further validation steps.</p></caption><graphic xlink:href="EMS202033-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>ADARreg silencing affects A to I editing in intronic regions.</title><p><bold>(A)</bold> Left, numbers of significative editing sites detected by RED-ML algorithm (FDR&lt; 0.05). Red bars represent the number of editing sites falling within Alu sequences, light blue bars the ones outside. Right, numbers of significative editing sites differentially present in the ibrutinib-resistant cells compared to parental cells, or in ibrutinib resistant ADARreg kd or lncPCED1b kd, respect to the KLK12kd negative control (pvalue&lt; 0.05, Limma test).</p><p><bold>(B)</bold> Cumulative bar graphs showing the percentual genomic distribution of the total significative editing sites, or of the significative differentially edited sites in the comparisons of ibrutinib resistant cells versus parental cells, or ibrutinib resistant ADARreg kd or lncPCED1b kd, respect to the KLK12kd negative control cells (pvalue&lt; 0.05, Limma test).</p><p><bold>(C)</bold> Log fold change (FC) distribution of differentially not-Alu edited sites within different genomic locations, in the comparison of ibrutinib resistant cells versus parental cells (left), or ibrutinib resistant ADARreg kd (middle) or lncPCED1b kd (right), respect to the KLK12kd negative control cells (pvalue&lt; 0.05, Limma test, mean and outlier values are shown).</p><p><bold>(D)</bold> Scatter plots of editing site log FC in the comparison resistant versus parental and ibrutinib resistant ADARreg kd cells versus KLK12kd control. Red dots represent editing sites statistically significant in the comparison ADARreg kd versus control. The regression line represents Pearson correlation (pvalue&lt; 0.05, Limma test).</p></caption><graphic xlink:href="EMS202033-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>IncPCED1b takes part to editome regulation with ADARreg.</title><p><bold>(A)</bold> Consensus sequence identified by MEME tool within all SMZL elncRNA sequences (top) or within SMZL super-enhancer DNA sequences.</p><p><bold>(B)</bold> Alignment of elncRNA consensus sequence and Alu element</p><p><bold>(C)</bold> RNA structure prediction of the SMZL elncRNA consensus sequence (left) or SMZL super-enhancer DNA consensus sequence (right). Thermodynamic stability of the structure is represented by the energy value calculated by RNAHybrid.</p><p><bold>(D)</bold> Scatter plots of ncRNA editing site Log FC in the comparison of ibrutinib-resistant ADARreg kd cells versus KLK12 kd control and ibrutinib-resistant versus parental. Blue dots represent significant differentially edited sites after ADARreg knockdown, red circled dots represent those significant differentially edited sites after ADARreg and lncPCED1b knockdown.</p><p><bold>(E)</bold> Scatter plot of editing site Log FC in the comparison ibrutinib resistant versus parental and ibrutinib resistant lncPCED1b kd cells versus KLK12kd control. Green dots represent editing sites statistically significant in the comparison lncPCED1b kd versus control.</p><p><bold>(F)</bold> Scatter plot of editing site Log FC in the comparison ibrutinib-resistant ADARreg kd cells versus control and ibrutinib-resistant lncPCED1b kd cells versus control. Red dots represent editing sites statistically significant in the comparison ADARreg kd versus control, green dots in the comparison lncPCED1b kd versus control. Genes that are significantly more or less edited after ADARreg kd and lncPCED1b kd, with respect to the KLK12 kd control, are listed in the boxes. The regression line represents Pearson correlation (pvalue&lt; 0.05, Limma test).</p></caption><graphic xlink:href="EMS202033-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>ADARreg modulates BTK inhibition response by regulating ADAR2 activity</title><p><bold>(A)</bold> Growth curve of ibrutinib resistant VL51 KLK12 or ADARreg kd built collecting green fluorescence of GFP+ mCherry + cells over 5 days under exposure to ibrutinib or vehicle</p><p><bold>(B)</bold> Growth curve of Jeko1 KLK12 or ADARreg kd built counting cells over 4 days under exposure to ibrutinib or vehicle</p><p><bold>(C)</bold> Growth curve of Jeko1 seeded 4 days after ADARreg LNA or negative control electroporation and built counting cells over 3 days under exposure to ibrutinib or vehicle.</p><p><bold>(D)</bold> The Kaplan-Meyer curve representing the overall survival of n=102 MCL patients dichotomized in n=49 high-level ADARreg expressor and n=53 low-expressor patients.</p><p><bold>(E)</bold> Pearson correlation of ADARreg and ADAR, top, or ADARB1, bottom, in 102 MCL patients.</p><p><bold>(F)</bold> Top, ADARB1 isoforms measured in total RNAseq performed in parental and ibrutinib resistant VL51 negative control cells and in ibrutinib resistant VL51 ADARreg kd. The corresponding protein isoform is reported at the bottom of the graph. * FDR&lt;0.05. Bottom, schematic representation of the isoforms ADARB1-204 and ADARB1-214.</p><p><bold>(G)</bold> Left, immunofluorescence of ADAR2 in parental VL51 or ibrutinib-resistant KLKL12 kd (negative control), top, or ADARreg kd or lncPCED1b kd monoclonal cell lines, bottom. DAPI stained nuclei, blue, Alexa647-conjugated antibody stained ADAR2, red. A blue and red fluorescence overlay was reported; a close-up from each picture shows a single-cell level magnification. Right, graph with nuclei/cytoplasm ratio of ADAR2 integrated density.</p></caption><graphic xlink:href="EMS202033-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>ADARreg modulates IRF3 activity</title><p><bold>(A)</bold> Preranked GSEA of RNAseq data in ibrutinib resistant VL51 KLK12 kd respect to parental VL51 KLK12 kd (yellow), after ADARreg knock down in ibrutinib resistant VL51 (grey), or lncPCED1b knock down (blue). Gene sets are represented based on decreasing enrichment score (NES), dot size is representative of statistical significance.</p><p><bold>(B)</bold> Scatter plot of logFC of interferon-stimulated genes in ibrutinib-resistant cells respect to parental cells and in ibrutinib-resistant cells VL51 ADARreg kd respect to negative control.</p><p><bold>(C)</bold> Scatter plots representing the comparison of changes in intronic (Δintron) and exonic (Δexon) reads per each expressed transcript in ibrutinib resistant VL51 ADARreg kd respect to KLK12 kd negative control. Δexon/Δintron=1 reflects transcriptional modulation, Δexon/Δintron≠1 reflects post-transcriptional modulation. Red dots represent robust post-transcriptionally modulated transcripts. P value&lt;0.05.</p><p><bold>(D)</bold> gProfiler gene ontology analysis of transcripts significantly modulated at post-transcriptional level after ADARreg kd.</p><p><bold>(E)</bold> IRF3 isoforms measured in total RNAseq performed in parental and ibrutinib resistant VL51 negative control cells and in ibrutinib resistant VL51 ADARreg kd. The corresponding protein isoform is reported at the bottom of the graph. * FDR&lt;0.05</p><p><bold>(F)</bold> IRF3 and IRF3a protein level quantification in ibrutinib resistance VL51 negative control cells and ibrutinib resistant VL51 ADARreg kd. Average of two independent biological replicates. * P &lt;0.05</p><p><bold>(G)</bold> Left, immunofluorescence of IRF3 in parental VL51 or ibrutinib-resistant KLKL12 kd (negative control), top, or ADARreg kd or lncPCED1b kd monoclonal cell lines, bottom. DAPI stained nuclei, blue, Alexa647-conjugated antibody stained IRF3, red. A blue and red fluorescence overlay was reported; a close-up from each picture shows a single-cell level magnification. Right, graph with nuclei/cytoplasm ratio of IRF3 integrated density.</p></caption><graphic xlink:href="EMS202033-f006"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><title>ADARreg alters transcript usage across key genes, like STING and NF-kB.</title><p><bold>(A)</bold> Top, STING1 isoforms measured in total RNAseq performed in parental and ibrutinib resistant VL51 negative control cells and ibrutinib resistant VL51 ADARreg kd. The corresponding protein isoform is reported at the bottom of the graph. Bottom, schematic representation of the two isoforms, as reported in Ensembl database. White boxes represent untranslated sequences, 5’UTR and 3’UTR. * FDR&lt;0.05</p><p><bold>(B)</bold> MTT assay performed in ibrutinib resistant VL51 ADARreg kd or KLK12 kd exposed to increasing doses of ibrutinib alone or in combination with STING agonist diABZI (10 μM), or vehicle for 96 h. Average of three independent biological replicates. * P &lt;0.05.</p><p><bold>(C)</bold> Left, RELA isoforms measured in total RNAseq performed in parental and ibrutinib resistant VL51 negative control cells and ibrutinib resistant VL51 ADARreg kd. The corresponding protein isoform is reported at the bottom of the graph. * FDR&lt;0.05. Right, Bar graph representing the ratio between the transcript producing the active p65 isoform and the N-terminal truncated p65.</p><p><bold>(D)</bold> p65 and N-terminal truncated p65 protein level quantification in ibrutinib-resistant VL51 negative control cells and ibrutinib-resistant VL51 ADARreg kd. Average of two independent biological replicates. * P &lt;0.05</p><p><bold>(E)</bold> Left, immunofluorescence of NF-kB in parental VL51 or ibrutinib-resistant KLKL12 kd (negative control), top, or ADARreg kd or lncPCED1b kd monoclonal cell lines, bottom. DAPI-stained nuclei, blue, Alexa647-conjugated antibody-stained NF-kB, red. A blue and red fluorescence overlay was reported; a close-up from each picture shows a single-cell level magnification. Right, graph with uclei/cytoplasm ratio of NF-kB integrated density.</p><p><bold>(F)</bold> Venn diagram intersecting total and sequence-specific edited transcripts significantly modulated in introns or 3’UTR and alternative transcriptional isoforms in ibrutinib-resistant VL51 after ADARreg kd.</p><p><bold>(G)</bold> Scheme of protein domains in RPS3 isoforms encoded by RPS3-203 or-208 transcripts.</p><p><bold>(H)</bold> Left, RPS3 isoforms measured in total RNAseq performed in parental and ibrutinib resistant VL51 negative control cells and ibrutinib resistant VL51 ADARreg or lncPCED1b kd. * FDR&lt;0.05. Right,</p><p><bold>(I)</bold> CLEC2D isoforms measured in total RNAseq performed in ibrutinib-resistant VL51 negative control cells and ibrutinib-resistant VL51 ADARreg. * FDR&lt;0.05.</p></caption><graphic xlink:href="EMS202033-f007"/></fig><fig id="F8" position="float"><label>Figure 8</label><caption><title>ADARreg inhibits NK cell-mediated cytotoxicity</title><p><bold>(A)</bold> Bar graph representing viable GFP+ mCherry+ ibrutinib resistant VL51, negative control or ADARreg kd, after 7 days of co-culture with activated healthy donor NK cells, normalized to the number of live tumor cells cultured alone.</p><p><bold>(B)</bold> Intercellular communication networks inferred by CellChat analysis between ADARreg<sup>high</sup>-like (blue) or ADARreg<sup>low</sup>-like (green) B cell and cytotoxic or inflammatory NK (red), or tumor-associated NK (TaNK) (brown), in ibrutinib slow responder CLL patient (CLL6).</p><p><bold>(C)</bold> Gene expression at single–cell level of CLEC2D and ADARreg signature in B cells of fast (left) or slow (right) ibrutinib-responder CLL patients at pretreatment (pink), after 30 days (green), 120 days (blue), or 280 days (purple, slow responder patient only) of ibrutinib treatment.</p></caption><graphic xlink:href="EMS202033-f008"/></fig></floats-group></article>